What is TARS's current stock price?

TARS (Tarsus Pharmaceuticals, Inc.) is currently trading at $62.26 with a market cap of $2.68B.

What sector is Tarsus Pharmaceuticals, Inc. in?

Tarsus Pharmaceuticals, Inc. (TARS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TARS a good stock to buy?

Analysts have a Buy consensus on TARS with a price target of $84.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TARS Tarsus Pharmaceuticals, Inc.

Healthcare

$62.26-1.92%ClosedMarket Cap: $2.68B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

7.66

P/S

5.01

EV/EBITDA

-68.14

DCF Value

$-436.98

FCF Yield

-1.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

90.4%

Operating Margin

-9.5%

Net Margin

-9.0%

ROE

-14.2%

ROA

-8.3%

ROIC

-11.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$162.1M	$-7.0M	$—
Q4 null	$151.7M	$-8.4M	$—
FY null	$451.4M	$-66.4M	$—
Q3 null	$118.7M	$-12.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$84.00

Target (Median)

$84.00

Target Range

$68.00 - $100.00

1 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-04

OppenheimerOutperform

2026-02-25

GuggenheimBuy

2026-02-25

GuggenheimBuy

2025-11-05

HC Wainwright & Co.Buy

2025-10-20

Trading Activity

Insider Trades

View All

PYOTT DAVID E Idirector

SellTue Apr 28

Neervannan Seshadriofficer: Chief Operating Officer

SellTue Mar 24

Whitfield Dianne C.officer: Chief Human Resources Officer

SellThu Mar 19

Whitfield Dianne C.officer: Chief Human Resources Officer

SellThu Mar 19

Whitfield Dianne C.officer: Chief Human Resources Officer

SellThu Mar 19

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.53

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Peers